Novogen Ltd. (NASDAQ: NVGN) 42.9% HIGHER; announced on 18th March, 2015 that one of its oncology pipeline drug candidates, Anisina (ATM-3507), has achieved a major milestone in its development, confirming the concept that comprehensive destruction of a cancer cell’s cytoskeleton can deliver a powerful anti-cancer effect.
Vitesse Semiconductor Corporation (Nasdaq: